Co-CEO Melissa Tomkiel trims stake at Strata Critical Medical (SRTA)

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.

Insider Trade Summary

Net Seller: 29,730 shares ($174,515)

Net Sell 1 txn

Insider Tomkiel Melissa M.

Role Co-CEO and General Counsel

Sold 29,730 shs ($175K)

Type	Security	Shares	Price	Value
Sale	Class A common stock, $0.0001 par value per share	29,730	$5.87	$175K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,892,774 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 29,730 shares Sale price: $5.87 per share Shares held after transaction: 1,892,774 shares +2 more

5 metrics

Shares sold 29,730 shares Open-market sale on June 8, 2026

Sale price $5.87 per share Class A common stock transaction

Shares held after transaction 1,892,774 shares Direct ownership following sale

Transaction type Open-market sale (Code S) Non-derivative Class A common stock

Transaction date June 8, 2026 Reported on Form 4

Key Terms

open-market sale, Class A common stock, Form 4, restricted stock units, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A common stock financial

"security_title: "Class A common stock, $0.0001 par value per share""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy tax withholding obligations in connection with the vesting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last)

(First)

(Middle)

C/O STRATA CRITICAL MEDICAL, INC.

666 THIRD AVENUE, 25TH FLOOR

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-CEO and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock, $0.0001 par value per share	06/08/2026		S		29,730⁽¹⁾	D	$5.87	1,892,774	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

	/s/ Melissa M. Tomkiel	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Strata Critical Medical (SRTA) report for Melissa Tomkiel?

Strata Critical Medical reported that Co-CEO Melissa M. Tomkiel sold 29,730 shares. The Form 4 shows an open-market sale of Class A common stock, reflecting a reduction in her directly held shares while she remains a significant shareholder.

At what price did Melissa Tomkiel sell Strata Critical Medical (SRTA) shares?

Melissa Tomkiel sold 29,730 Strata Critical Medical shares at $5.87 each. The transaction was reported as an open-market sale of Class A common stock, giving investors visibility into the pricing of this insider disposition.

How many Strata Critical Medical (SRTA) shares does Melissa Tomkiel hold after the sale?

After the reported sale, Melissa Tomkiel directly holds 1,892,774 shares. This post-transaction balance, disclosed in the Form 4, indicates she continues to maintain a large equity position in Strata Critical Medical despite the recent sale.

What role does Melissa Tomkiel hold at Strata Critical Medical (SRTA)?

Melissa M. Tomkiel serves as Co-CEO and General Counsel of Strata Critical Medical. The Form 4 filing identifies her as both a director and officer, which is why her equity transactions must be publicly reported to the SEC.

Was the Strata Critical Medical (SRTA) insider transaction an open-market sale?

Yes, the transaction is characterized as an open-market sale. The Form 4 lists transaction code “S” and describes it as a sale in an open market or private transaction, distinguishing it from option exercises, gifts, or tax-withholding events.